REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial tests new Two-Drug attack on Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for patients with certain types of lymphoma that have come back or stopped responding to previous treatments. The main goals are to find the safest dose and understand the side effects of …
Matched conditions: REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug duo tested in fight against stubborn lymphoma
Disease control OngoingThis early-stage study is testing the safety and best dose of a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has come back or hasn't responded to other treatments. The goal is to see if this combination can help control the cancer. The stud…
Matched conditions: REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Early trial launches Four-Pronged attack on Tough-to-Treat blood cancer
Disease control OngoingThis early-stage study is testing a new four-drug combination for a very aggressive type of lymphoma that has returned or stopped responding to standard treatments. The goal is to see if combining an immunotherapy drug (atezolizumab) with two chemotherapy drugs and a targeted ant…
Matched conditions: REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive lymphoma
Disease control OngoingThis study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…
Matched conditions: REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC